Michael J. Pishvaian

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Michael S. Lee, Baek‐Yeol Ryoo, Chih‐Hung Hsu et al. · The Lancet Oncology · 2020 · 555 citations

Phase 1B, Hepatology, Medicine +8

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

Michael J. Pishvaian, Edik M. Blais, Jonathan R. Brody et al. · The Lancet Oncology · 2020 · 517 citations

Prognostic Biomarkers, Pancreatic Cancer, Overall Survival +11

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

Patrick A. Ott, Yung‐Jue Bang, Dominique Berton-Rigaud et al. · Journal of Clinical Oncology · 2017 · 504 citations

Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer Types

Arielle L. Heeke, Michael J. Pishvaian, Filipa Lynce et al. · JCO Precision Oncology · 2018 · 451 citations

Sorafenib for Advanced and Refractory Desmoid Tumors

Mrinal M. Gounder, Michelle R. Mahoney, Brian A. Van Tine et al. · New England Journal of Medicine · 2018 · 431 citations · Full text